By applying AI algorithms, mjn-SERAS is able to interpret the brain signal, record epileptic seizures, objectively improve the medical monitoring and permanently assess the risk of suffering a seizure in the next minute to prevent the patient from suffering an accident. During the years 2018 and 2019 clinical trials were carried out to validate the results of the pilot test carried out in 2017. As a result, we will obtained the CE mark in 2020 and started our first sales the same year. Now we are selling in Spain and expanding to the UK and The Netherlands.

In a future, mjn-SERAS will also be able to use electroencephalography readings to help patients with other neurological diseases such as Alzheimer, Parkinson and/or Schizophrenia.